CRIPTO’s multifaceted role in driving aggressive prostate cancer unveiled by in vivo, organoid, and patient data
Oncogene – CRIPTO’s multifaceted role in driving aggressive prostate cancer unveiled by in vivo, organoid, and patient data
Related Articles
How to thank your lab mates: eight ways to show gratitude at the end of year
Nature – Alongside secret Santas and seasonal parties, many laboratories develop traditions to show appreciation to colleagues — from sweets and mulled wine to quizzes…
Research Aims to Expand RAS Inhibitor Options in Pancreatic Cancer
Brandon G. Smaglo, MD, FACP, discusses ongoing research with novel RAS inhibitors in pancreatic cancer.
Incidence and Characterization of Secondary CNS Lymphoma in 1,972 Patients with DLBCL – A Danish Nationwide Cohort Study
Key Points. The cumulative incidence of SCNSL was 2.6% at two years with death and relapse without CNS involvement as competing risksThe most significant p
Advancing Predictive Biomarkers for Colon Cancer Treatment : Oncology Times
An abstract is unavailable.
COMPARABLE OUTCOMES AFTER BUSULFAN- OR TREOSULFAN-BASED CONDITIONING FOR ALLO-HSCT IN CHILDREN WITH ALL-RESULTS OF FORUM
Key Points. Chemo conditioning with busulfan- or treosulfan-based regimens yields comparable outcomes for allo-HSCT in children with ALL.Either regimen can
An update on autoantibodies in the idiopathic inflammatory myopathies
Nature Reviews Rheumatology – This Review provides an update on autoantibodies associated with idiopathic inflammatory myopathies in both adults and children. The authors also discuss…
Patient navigation benefits health systems, improves care Initial data presented at the White House come a year after CMS payment began – The Cancer Letter
One year after the Centers for Medicare & Medicaid Services made the decision to pay for patient navigation services, data from early adopters show that…
Biomarker Testing in NSCLC: Best Practices for Personalized Medicine
Panelists discuss how the interpretation of HER2 IHC scores informs treatment decisions in NSCLC, including adherence to ASCO/CAP guidelines and strategies for managing equivocal results.
